Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings

This article was originally published in The Tan Sheet

Executive Summary

CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.

You may also be interested in...



Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch

Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.

Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch

Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.

Infirst Extends Mylanta Brand With Nighttime Product, Chewable Tablets

Infirst changes the Mylanta Maximum Strength lemon-mint liquid with a "smoother, creamier formulation" and adds a vanilla caramel-flavored version and another liquid product, Mylanta Tonight, featuring a honey chamomile flavor. Also new are Mylanta Gas Minis chewable anti-gas tablets.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS107735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel